Molecular targeted therapies for solid tumors: Management of side effects

Onkologie

Volumn 32, Issue 3, 2009, Pages 129-138

  Grünwald, Viktor ^a   Soltau, Jens ^b   Ivanyi, Philipp ^a   Rentschler, Jochen ^b   Reuter, Christoph ^a   Drevs, Joachim ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Cancer Hospital Sanafontis   (Germany)

Author keywords

Adverse event; Kinase inhibitors; Management; Molecular targeted therapy

Indexed keywords

AFINITOR; BEVACIZUMAB; CAPECITABINE; CEDIRANIB; CELECOXIB; CETUXIMAB; CORTICOSTEROID; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; METRONIDAZOLE; MONOCLONAL ANTIBODY; PANITUMUMAB; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDOXINE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TETRACYCLINE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANEMIA; ANGINA PECTORIS; ARTICLE; ASCITES; BLEEDING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DESQUAMATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG TARGETING; DRUG TOLERABILITY; DRY SKIN; EDEMA; EPISTAXIS; FATIGUE; HAIR DISCOLORATION; HAIR LOSS; HAND FOOT SYNDROME; HEART INFARCTION; HOARSENESS; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INTESTINE ISCHEMIA; LUNG EMBOLISM; LUNG HEMORRHAGE; MACULOPAPULAR RASH; METABOLIC DISORDER; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; NAIL INFECTION; NEUTROPENIA; PLEURA EFFUSION; PORTAL VEIN THROMBOSIS; PROTEINURIA; RASH; SIDE EFFECT; SKIN PRURITUS; SKIN TOXICITY; SOLID TUMOR; STOMATITIS; STROKE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; THYROID DISEASE; TRANSIENT ISCHEMIC ATTACK; VEIN THROMBOSIS; VESICULAR RASH; WOUND HEALING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 63849189675     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000194949     Document Type: Article

References (55)

1. Drevs J, Laus C, Medinger M, Schmidt-Gersbach C, Unger C: Antiangiogenesis: Current clinical data and future perspectives. Onkologie 2002;25:520-527.
2. Grunwald V, Heinzer H, Fiedler W: Managing side effects of angiogenesis inhibitors in renal cell carcinoma. Onkologie 2007;30:519-524.
3. Widakowich C, de Castro G, Jr, Azambuja E, Dinh P, Awada A: Review: Side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007;12:1443-1455.
4. Gridelli C, Maione P, Rossi A: The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist 2008;13:139-147.
5. Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenbilt A: Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008;19(suppl 2):ii47-48.
6. Hurwitz H, Fehrenbacher L, NovotnyW, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
7. Van Cutsem E, Michael M, Berry S, Dibartolomeo M, Rivera F, Kretzschmar A, Mazier M, Lutiger B, Cunningham D: Preliminary safety and efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI, and capecitabine for mCRC: First BEA-Trial. ASCO GI 2007;abstr 346.
8. Horowitz JR, Rivard A, van der Zee R, Hariawala M, Sheriff DD, Esakof DD, Muqtada Chaudhry G, Symes JF, Isner JM: Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vase Biol 1997;17:2793-2800.
9. Langenberg M, van Herpen CM, De Bono JS, Unger C, Schellens JH, Hoekman K, Blum HE, Le Maulf F, Fielding F, Voest EE: Optimal management of emergent hypertension during treatment with a VEGF signaling inhibitor: A randomized phase II study of cediranib. J Clin Oncol 2008;26(suppl):abstr 3555.
10. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebeis M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM: Sorafenib in advanced clearcell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
11. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124.
12. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
13. Cohen MH, Gootenberg J, Keegan P, Pazdur R: FDA drug approval summary: Bevacizumab (avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007;12:713-718.
14. Verheul HM, Pinedo HM: Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007;7:475-485.
15. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
16. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35.
17. Lacouture ME: Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6:803-812.
18. Saltz LB, Meropol NJ, Loehrer PJ, Sr, Needle MN, Kopit J, Mayer RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-1208.
19. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL: Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85.
20. Perez-Soler R, Saltz L: Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining? J Clin Oncol 2005;23:5235-5246.
21. Nanney LB, Stoscheck CM, King LE, Jr, Underwood RA, Holbrook KA: Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 1990;94:742-748.
22. Mimeault M, Bonenfant D, Batra SK: New advances on the functions of epidermal growth factor receptor and ceramides in skin cell differentiation, disorders and cancers. Skin Pharmacol Physiol 2004;17:153-166.
23. Strumberg D, Awada A, Hirte H, Clark JW, Seeber S, Piccart P, Hofstra E, Voliotis D, Christensen O, Brueckner A, Schwartz B: Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer 2006;42:548-556.
24. Moss KG, Toner GC, Cherrington JM, Mendel DB, Laird AD: Hair depigmentation is a biological readout for pharmacological inhibition of kit in mice and humans. J Pharmacol Exp Ther 2003;307:476-480.
25. Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, Jurgensmeier JM, Puchalski TA, Young H, Saunders O, Unger C: Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25:3045-3054.
26. Mortimer JE, Lauman MK, Tan B: Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabine. J Oncol Pharm Pract 2003;9:161-166.
27. Lin E, Morris JS: Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology 2002;16(suppl 14):31-37.
28. Wood LS: Managing the side effects of sorafenib and sunitinib. Commun Oncol 2006;3:558-562.
29. Gressett SM, Stanford BL, Hardwicke F: Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Practice 2006;12:131-141.
30. www.mascc.org/media/Resource-centers/Guidelines-mucositis.pdf.
31. www.onkosupport.de/asors/content.
32. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM: Sorafenib in advanced clearcell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
33. Moy B, Goss PE: Lapatinib-associated toxicity and practical management recommendations. Oncologist 2007;12:756-765.
34. Sharma R, Tobin P, Clarke SJ: Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol 2005;6:93-102.
35. Zhu X, Wu S, Dahut WL, Parikh CR: Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007;49:186-193.
36. Saif MW, Mehra R: Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin Drug Saf 2006;5:553-566.
37. Frangie C, Lefaucheur C, Medioni J, Jacquot C, Hill GS, Nochy D: Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007;8:177-178.
38. Kilickap S, Abali H, Celik I: Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003;21:3542; author reply 3543.
39. Shah MA, Ilson D, Kelsen DP: Thromboembolic events in gastric cancer: High incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol 2005;23:2574-2576.
40. Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow L, Jaffe C, Rubinstein L, Zwiebel J, Kaplan RS: Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: An NCI treatment referral center trial TRC-0301. J Clin Oncol 2006;24:3354-3360.
41. Roncalli J, Delord JP, Galinier M, Massabuau P, Lescure M, Fauvel JM, Azria D: Bevacizumab in metastatic colorectal cancer: A left intracardiac thrombotic event. Ann Oncol 2006;17:1177-1178.
42. Yoon S, Schmassmann-Suhijar D, Zuber M, Konietzny P, Schmassmann A: Chemotherapy with bevacizumab, irinotecan, 5-fluorouracil and leucovorin (IFL) associated with a large, embolizing thrombus in the thoracic aorta. Ann Oncol 2006;17:1851-1852.
43. Kuenen BC, Rosen L, Smit EF, Parson MR, Levi M, Ruijter R, Huisman H, Kedde MA, Noordhuis P, van der Vijgh WJ, Peters GJ, Cropp GF, Scigalla P, Hoekman K, Pinedo HM, Giaccone G: Dosefinding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002;20:1657-1667.
44. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H: Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Nat Cancer Inst 2007;99:1232-1239.
45. Eskens FA, Verweij J: The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006;42:3127-3139.
46. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM: Hypothyroidism in patients with metastatic renal cell Carcinoma treated with sunitinib. J Natl Cancer Inst 2007;99:81-83.
47. Wolter P, Dumez H, Schoffski P: Sunitinib and hypothyroidism. N Engl J Med 2007;356:1580; author reply 1580-1581.
48. Garfield D, Hercbergs A, Davis P: Unanswered questions regarding the management of sunitinibinduced hypothyroidism. Nat Clin Pract Oncol 2007;4:674.
49. Wang JF, Milosveski V, Schramek C, Fong GH, Becks GP, Hill DJ: Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. J Endocrinol 1998;157:5-12.
50. Reuter CW, Morgan MA, Grunwald V, Herrmann TR, Burchardt M, Ganser A: Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma. World J Urol 2007;25:59-72.
51. Fischer C, Carmeliet P, Conway EM: VEGF inhibitors make blood. Nat Med 2006;12:732-734.
52. Tam BY, Wei K, Rudge JS, Hoffman J, Holash J, Park SK, Yuan J, Hefner C, Chartier C, Lee JS, Jiang S, Niyak NR, Kuypers FA, Ma L, Sundram U, Wu G, Garcia JA, Schrier SL, Maher JJ, Johnson RS, Yancopoulos GD, Mulligan RC, Kuo CJ: VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006;12:793-800.
53. Ryan CJ, Stadler WM, Roth B, Hutcheon D, Conry S, Puchalski T, Morris C, Small EJ: Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs 2007;25:445-451.
54. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
55. Heuchel R, Berg A, Tallquist M, Ahlen K, Reed RK, Rubin K, Claesson-Welsh L, Heldin CH, Soriano P: Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3' kinase signaling. Proc Natl Acad Sci U S A 1999;96:11410-11415.